Created at Source Raw Value Validated value
June 25, 2024, noon usa

1. general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation. 2. colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil, hiv protease inhibitor, azole antifungal, or macrolide antibiotic (except azithromycin). 3. asa: allergy; high risk of bleeding, current or planned use of other anti-thrombotic drugs (e.g., p2y12 inhibitors, direct oral anticoagulants, vitamin k antagonists, heparins) inpatient trial: inclusion criteria: 1. symptomatic and laboratory-confirmed diagnosis of covid-19. 2. age ≥18 years. 3. within 72 hours (ideally 24 hours) of admission, or worsening clinically.

1. general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation. 2. colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil, hiv protease inhibitor, azole antifungal, or macrolide antibiotic (except azithromycin). 3. asa: allergy; high risk of bleeding, current or planned use of other anti-thrombotic drugs (e.g., p2y12 inhibitors, direct oral anticoagulants, vitamin k antagonists, heparins) inpatient trial: inclusion criteria: 1. symptomatic and laboratory-confirmed diagnosis of covid-19. 2. age ≥18 years. 3. within 72 hours (ideally 24 hours) of admission, or worsening clinically.

Nov. 16, 2021, 6:30 p.m. usa

general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation. colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil, hiv protease inhibitor, azole antifungal, or macrolide antibiotic (except azithromycin). asa: allergy; high risk of bleeding, current or planned use of other anti-thrombotic drugs (e.g., p2y12 inhibitors, direct oral anticoagulants, vitamin k antagonists, heparins) inpatient trial: inclusion criteria: symptomatic and laboratory-confirmed diagnosis of covid-19. age ≥18 years. within 72 hours (ideally 24 hours) of admission, or worsening clinically.

general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation. colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil, hiv protease inhibitor, azole antifungal, or macrolide antibiotic (except azithromycin). asa: allergy; high risk of bleeding, current or planned use of other anti-thrombotic drugs (e.g., p2y12 inhibitors, direct oral anticoagulants, vitamin k antagonists, heparins) inpatient trial: inclusion criteria: symptomatic and laboratory-confirmed diagnosis of covid-19. age ≥18 years. within 72 hours (ideally 24 hours) of admission, or worsening clinically.

Oct. 26, 2020, 11:31 p.m. usa

1. general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation. 2. colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil, hiv protease inhibitor, azole antifungal, or macrolide antibiotic (except azithromycin). 3. asa: allergy; high risk of bleeding, current or planned use of other anti-thrombotic drugs (e.g., p2y12 inhibitors, direct oral anticoagulants, vitamin k antagonists, heparins) inpatient trial: inclusion criteria: 1. symptomatic and laboratory-confirmed diagnosis of covid-19. 2. age ≥18 years. 3. within 72 hours (ideally 24 hours) of admission, or worsening clinically.

1. general: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation. 2. colchicine: allergy or planned use; current or planned use of cyclosporine, verapamil, hiv protease inhibitor, azole antifungal, or macrolide antibiotic (except azithromycin). 3. asa: allergy; high risk of bleeding, current or planned use of other anti-thrombotic drugs (e.g., p2y12 inhibitors, direct oral anticoagulants, vitamin k antagonists, heparins) inpatient trial: inclusion criteria: 1. symptomatic and laboratory-confirmed diagnosis of covid-19. 2. age ≥18 years. 3. within 72 hours (ideally 24 hours) of admission, or worsening clinically.